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Background:  Microemulsion propofol produces more frequent and severe pain upon injection than lipid emulsion 
propofol.  This study examined the analgesic effect of lidocaine-premixed microemulsion propofol in patients 
pretreated with remifentanil.  The induction of anesthesia with this combination was compared with microemulsion 
propofol accompanied with either remifentanil or lidocaine. 
Methods:  One hundred twenty patients aged between 20-65 years old were allocated randomly into one of three 
groups (n = 40, in each).  The patients in the remifentanil group received remifentanil 0.5 μg/kg IV for 30 seconds 
before a microemulsion propofol injection.  The patients in the lidocaine group received propofol 2 mg/kg premixed 
with 40 mg lidocaine over a 60 second period.  The patients in the combination group received both remifentanil and 
lidocaine.
Results:  There was a significantly lower incidence of microemulsion propofol injection pain (severity 2 or more) in 
the combination group (12.5%) than in the remifentanil and lidocaine groups (90% and 65%, respectively, P < 0.05).   
The incidence of moderate pain disappeared completely in the combination group (0%) compared to that in the 
remifentanil and lidocaine group (32.5% and 20%, respectively, P < 0.05).  Severe pain did not appear in any of the 
three groups.  There were no complications on the injection site in the lidocaine alone and combination groups. 
Conclusions:  The combination of microemulsion propofol premixed with lidocaine after a pretreatment with 
remifentanil was more effective in reducing the incidence of pain upon the injection of microemulsion propofol than 
either treatment alone.  (Korean J Anesthesiol 2010; 58: 435-439)
Key Words:  Intravenous anesthetics, Lidocaine, Microemulsion propofol, Pain, Remifentanil.
Pain reduction on injection of microemulsion propofol via 
combination of remifentanil and lidocaine
Yong Ku Han, Cheol Won Jeong, and Hyung Gon Lee
Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju, Korea 
Received: December 30, 2009.  Revised: 1st, January 22, 2010; 2nd, February 10, 2010.  Accepted: March 23, 2010.
Corresponding author: Hyung Gon Lee, M.D., Ph.D., Department of Anesthesiology and Pain Medicine, Chonnam National University Medical 
School, 671, Jebong-no, Dong-gu, Gwangju 501-757, Korea. Tel: 82-62-220-6893, Fax: 82-62-232-6294, E-mail: leehg@chonnam.ac.kr
The 86th Annual Scientific Meeting of Korea Society of Anesthesiologists, 2008, Jeju, Korea.
    This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
CC436 www.ekja.org
Injection pain of microemulsion propofol Vol. 58, No. 5, May 2010
Introduction
    Despite its many advantages, propofol is also associated with 
some anesthetic challenges, such as difficulty in developing 
an injectable formulation, significant decreases in blood-
pressure at a normal induction dose, and prominent pain at 
the peripheral intravenous injection sites [1]. Those problems 
are associated with the currently used long-chain triglyceride 
formulations but may provide further pharmaceutical 
opportunity to develop a newer and better generation of 
propofol. 
    A lipid-free microemulsion propofol (Aquafol
Ⓡ; Daewon 
Pharmaceutical Co., Ltd, Seoul, Korea), which is composed 
of 1% propofol, 10% purified poloxamer 188 (PP188) as a 
nonionic block copolymer surfactant and 0.7% polyethylene 
glycol 660 hydroxystearate as a nonionic surfactant, was 
developed to avoid the risk of adverse lipid solvent-related 
drug reactions, such as fat embolism, postoperative infection, 
hypertriglyceridaemia and pancreatitis [2], However, 
microemulsion propofol produces more frequent and severe 
pain upon injection than long-chain triglyceride propofol [3].
    Many techniques have been suggested to prevent such pain 
with varying degrees of success. These include premedication 
[4], rapid injection [5], dilution or changing the temperature of 
propofol [6], use of local anesthetics [7-9], and pre-treatment 
with systemic opioids [10-12]. However, none has achieved the 
complete elimination of pain. Recent studies revealed that a 
combination of two different analgesic modalities, opioids and 
lidocaine, can reduce the incidence and severity of propofol 
injection pain compared to each drug alone in adults [13,14].
    This study examined the analgesic effect of microemulsion 
propofol premixed with lidocaine after a pretreatment with 
remifentanil, and compared the effect with that of each 
treatment alone.
Materials and Methods
    After obtaining approval from the institutional review board 
and informed consent, the study was carried out prospectively 
on 120 ASA (American Society of Anesthesiologists) physical 
status I or II patients aged between 20-65 years, who underwent 
general anesthesia for elective surgery. Patients with self-con-
firming allergies to opioids, local anesthetics, asthma, neuro-
logical deficits and those who had received analgesics or seda-
tives within the previous 24 hours were excluded. 
    No premedication was administered prior surgery. Before 
arriving at the operating room, a 20 gauge cannula was inserted 
in the left cephalic vein, and its position was confirmed by the 
free flow of a Hartmann’s solution infused by gravity. Upon 
arrival at the operating room, all patients were monitored with 
an electrocardiogram, pulse oximeter and non-invasive arterial 
pressure. 
    The patients were allocated randomly to one of three groups 
using a computer generated randomization list manipulated by 
a statistician in a sealed envelope. An independent researcher 
prepared the study syringe for each patient. The patients’ 
characteristics were similar in the three groups (Table 1). No 
patient was excluded from the analysis due to complications, 
hence the data for all 120 patients is presented. Regarding the 
treatment groups, the remifentanil group received remifentanil 
0.5 μg/kg intravenously (diluted with normal saline) for 30 s 
and at 60 s later patients were given 2 mg/kg microemulsion 
propofol for 60 s. The lidocaine group received 2 mg/kg 
microemulsion propofol premixed with lidocaine 40 mg over a 
60 s period. The combination group received remifentanil 0.5 
μg/kg IV (diluted with normal saline) over a 30 s period, and 60 s 
later, the patients were given microemulsion propofol premixed 
with lidocaine 40 mg over a 60 s period. After the remifentanil 
injection, the Observer’s Assessment of Alertness and Sedation 
(OAA/S) scale was checked to subjectively assess the level of 
consciousness to ensure an adequate response to the pain 
questionnaires [15]. The mean arterial pressure and heart rate 
were recorded before injecting the study drug (baseline), after 
the remifentanil injection, after the microemulsion propofol 
injection and 1 minute after tracheal intubation.
    The patients, anesthesia providers and investigators who 
scored the movements were blinded to the treatment group. 
All study drugs were prepared before the injection at room 
temperature. Microemulsion propofol (Aquafol
Ⓡ, 1% propofol, 
Daewon Pharmaceutical Co., Ltd, Seoul, Korea) was mixed 
with 2 ml of lidocaine 2% (or normal saline 2 ml). All drugs 
were administered through a rubber port connected to the 
intravenous cannula with a free flow of fluid. After preoxy-
genation, general anesthesia was induced with 2 mg/kg 
microemulsion propofol. Mask ventilation was initiated with 
oxygen 100% once the patient had become unconscious 
and apneic. The patients’ response after the microemulsion 
propofol injection was graded by the investigator according to 
the following four-point scale, as previously described [16]: 1, 
no pain (no reaction to the injection); 2, slight pain (a minor 
Table 1. Demographic Data 
  Lidocaine
(n = 40)
Remifenatnil
(n = 40)
Combination
(n = 40)
Sex (M/F)
Age (yr)
Weight
Height
20/20
      47 (14.5)
  64.0 (11.1)
164.0 (8.0)
20/20
      51 (13.5)
60.8 (7.4)
162.4 (8.2)
19/21
     50 (14.4)
  63.8 (10.5)
162.9 (8.8)
Values are shown as mean (SD) or number of patients.  There were 
no significant differences between groups.437 www.ekja.org
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verbal/facial response or motor reaction to the injection); 
3, moderate pain (a clear verbal/facial response or motor 
reaction to the injection); and 4, severe pain (the patient both 
complained of pain and withdrew their arm).
    The assessment was made from the start of the microemulsion 
propofol injection to the point when the patients had lost 
consciousness. The investigator also recorded the incidence 
of cough, chest rigidity and breath holding. After the loss of an 
eyelash reflex, the patients were intubated after administering 
rocuronium 0.8 mg/kg. Anesthesia was maintained with sevo-
flurane 2.0% to 2.5% and nitrous oxide 50% in oxygen. 
    The sample size calculation was based on preliminary data. 
In a one-way ANOVA study, sample sizes of 37, 37, and 37 were 
obtained for the 3 groups, whose means of incidence were to 
be compared. The total sample of 111 subjects was found to be 
sufficient to achieve 80% power to detect differences between 
the means versus the alternative of equal means using an F test 
with a 0.05 significance level. The size of the variation in the 
means is represented by their standard deviation, 15.05. The 
common standard deviation within a group was assumed to 
be 50. The sample size was increased to 40 patients per group 
assuming the occurrence of dropouts.
    Statistical analyses were performed using SPSS software 
(version 12.0, SPSS Inc., IL, USA). A Fisher’s exact test was used 
to calculate the between-group differences in the incidence 
of microemulsion-induced pain, and a Kruskal-Wallis test 
was used to assess the differences in the mean pain-intensity 
scores. P value < 0.05 was considered significant. All values are 
expressed as the mean (SD) or absolute numbers (%).
Results
    The incidence of pain from a microemulsion propofol injection 
(severity 2 or more) was significantly lower in the combination 
group (12.5%) than that in the remifentanil and lidocaine 
groups (90% and 65%, respectively, P < 0.05) (Table 2). The 
incidence of moderate pain disappeared completely in the 
combination group (0%), compared to that in the remifentanil 
and lidocaine groups (32.5% and 20%, respectively, P < 0.05).
    No case of severe pain was observed in any of the three groups 
(Table 2). For all subjects, the OAA/S levels were 5 (prompt re-
sponse to name spoken in a normal tone), indicating adequate 
responses to the questionnaires.
    The heart rate (HR) and mean arterial pressure (MAP) were 
maintained within the normal limits in all three groups and 
there was no hypotension or bradycardia encountered during 
the study period (Fig. 1). None of the patients suffered from 
desaturation, apnea, chest wall rigidity, cough or other adverse 
effects during the induction of anesthesia. Only three patients 
in the remifentanil group had a little wheal reaction on the 
injection site but those responses disappeared within a few 
minutes.
Discussion
    Propofol-induced pain has been ranked by American anes-
thesiologists as the seventh most important problem of current 
clinical anesthesiology [17]. The nature of pain is extreme 
aching, burning and crushing. Pain during propofol injection 
can be immediate or delayed, and delayed pain, which is has 
been attributed to an interaction with nociceptors and free 
nerve endings, has a latency of between 10 and 20 seconds [18]. 
    This study demonstrated that a combination of a pretreatment 
with remifentanil 0.5 μg/kg and premixture of 40 mg lidocaine 
Table 2. Incidence and Severity of Pain on a Propofol Injection
Severity of pain
Lidocaine
(n = 40)
Remifentanil
(n = 40)
Combination
(n = 40)
1 (No pain)
2 (Mild pain)
3 (Moderate pain)
4 (Severe pain)
14 (35)
18 (45)
  8 (20)
0 (0)
 4 (10)
   23 (57.5)
   13 (32.5)
0 (0)
        35 (87.5)*,†
          5 (12.5)*,†
0 (0)
0 (0)
The values are shown as the number of patients (%).  *P < 0.05 com-
pared to the lidocaine group, 
†P < 0.05 compared ro the remifentanil 
group.
Fig. 1. Hemodynamic changes after the propofol and remifentanil 
injection. The blood pressure and heart rate are the mean values 
that were maintained within the normal limits in all three groups 
and there was no hypotension or bradycardia during the study 
period. MBP baseline: MBP before injecting the study drug, MBP 
remifentanil: MBP after the remifentanil injection, MBP Aquafol: 
MBP after the Aquafol injection, MBP intubation: MBP 1 min after 
intubation. HR baseline: baseline HR, HR remifentanil: HR after the 
remifentanil injection, HR Aquafol: HR after the Aquafol injection, 
HR intubation: HR 1 min after intubation. MBP: mean blood 
pressure, HR: heart rate.438 www.ekja.org
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and microemulsion propofol was more effective in reducing the 
incidence of pain on an injection of microemulsion propofol 
than each treatment alone. 
    The more frequent and severe pain of the microemulsion 
propofol injection than that of lipid emulsion propofol is a 
common and difficult problem. A recent study demonstrated 
that the incidence of pain (VAS > 30 mm) on injection with 
microemulsion and lipid emulsion propofol was 69.7% and 
42.3%, respectively, and the median (25%, 75%) VAS scores 
for pain on injection with microemulsion and lipid emulsion 
propofol were 59 (25, 85) and 24 (0, 50) mm, respectively. The 
significantly higher incidence and severity of pain on injection 
with microemulsion propofol are associated with a sevenfold 
increase in the aqueous free propofol concentration [3].
    The most popular technique for reducing the injection pain 
of propofol is to mix lidocaine with propofol [9]. Lidocaine may 
act by stabilizing the kinin cascade [7], which is activated by 
contact with free propofol [19]. The analgesic effect of lidocaine 
on a propofol injection is based not only on its local anesthetic 
effects, but also on the decrease in pH of the propofol-lidocaine 
mixture [20]. 
    Pretreatment with opioids has been reported to reduce the 
incidence and severity of pain during a propofol injection with 
varying results [10-12]. Remifentanil is a piperidine-based 
opioid that acts as a μ-receptor agonist. Its pharmacokinetic 
profile is unique among opioids with very rapid plasma 
clearance and onset time and a very short context-sensitive half-
life of 2-10 min. Therefore, remifentanil appears to be a very 
titratable opioid providing profound intraoperative analgesia for 
either very brief periods in which analgesia is required or over 
prolonged periods without any concern for prolonged recovery 
[21]. Similar to other opioids, the action site of remifentanil may 
either be central or peripheral. Our assumption was that the 
pain-reducing action of remifentanil would mainly be central 
because a tourniquet technique was not used and adequate 
time was allowed for the onset of remifentanil.
    In this study, the injection pain of microemulsion propofol 
was reduced to 12.5% of patients in the combination group. In 
contrast, 65-90% of patients in the lidocaine and remifentanil 
groups suffered from a painful injection. These results suggest 
that remifentanil enhances the analgesic efficacy of the 
lidocaine premixture. Further study elucidating the mechanism 
of this effect is needed.
    Although the decrease in HR and MAP before intubation was 
statistically significant in the remifentanil and combination 
groups, the MAP and HR before intubation were maintained 
within the normal limits (variation < 20%). This study had some 
limitations. First, the sample size was relatively small despite 
the sufficient number of patients according to power analysis. 
Second, a non-treated control group was not included in this 
study. 
    In conclusion, the combination treatment of two different 
analgesic modalities, remifentanil and lidocaine, prevents the 
moderate and severe pain on microemulsion propofol injection, 
and reduces the incidence of mild pain compared to each drug 
alone.
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